Please login to the form below

Not currently logged in

cell cancer

This page shows the latest cell cancer news and features for those working in and with pharma, biotech and healthcare.

Merck’s Keytruda meets survival challenge in NSCLC

Merck’s Keytruda meets survival challenge in NSCLC

Merck &Co’s grip on the first-line non-small cell lung cancer (NSCLC) immunotherapy market seems set to tighten, after its PD-1 inhibitor Keytruda halved the risk of death ... The first look at data from the KEYNOTE-189 study, presented at the American

Latest news

More from news
Approximately 1 fully matching, plus 627 partially matching documents found.

Latest Intelligence

  • The good, the bad and the ugly The good, the bad and the ugly

    Merck’s success in oncology will likely continue, driven by Keytruda’s lead in the frontline non-small cell lung cancer setting, ”says Cai Xuan, senior analyst, oncology and haematology, GlobalData. ... It will also be interesting to see how gene

  • Digital disruption Digital disruption

    That cloud-based tool, called the BioModel Analyzer (BMA), brings alive the millions of potential changes in cell signalling that make cancer cells multiply uncontrollably. ... Next, they draw in the basic signalling pathways that can go wrong in cancer

  • Deal Watch February 2017 Deal Watch February 2017

    triple-negative breast cancer (TNBC), small-cell lung cancer (SCLC), non-small-cell lung cancer (NSCLC) and pancreatic cancer. ... Licence. 320. Lonza/ Sanofi. Large scale mammalian cell manufacturing facility for antibody therapeutics.

  • Deal Watch January 2017 Deal Watch January 2017

    Using a similar structure, Takeda also announced a collaboration with possible future acquisition of Maverick which focuses on next-generation T-cell cancer research. ... 160. Kite Pharma. Fosun Pharma. Formation of a JV. Autologous T-cell therapies in

  • Opening up innovation Opening up innovation

    A surprising inclusion in GSK's R&D hopes - given the 2015 swap of its cancer drugs business for Novartis' interests in vaccines - is its continued efforts in oncology. “ ... So that is really about the late-stage portfolio. We [are still] focused on

More from intelligence
Approximately 0 fully matching, plus 30 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest from PMHub

  • A stumble, but not a fall – what’s next for Opdivo?

    In this manner, it can crucially target several cancers, a property that was successfully exploited by BMS and resulted in securing FDA nods for treating non-small cell lung cancer (NSCLC) ... and renal cell carcinoma (kidney cancer).

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
Cello Health Insight

Cello Health Insight is the global market research arm of Cello Health. With 35 years’ sector experience, we specialise in...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...